Menu
← Oncology Approval Tracker
FDA DECISION ·
Abecma
idecabtagene vicleucel · Celgene (Bristol Myers Squibb)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after at least two prior lines that included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.
LAMPGEN ANALYSIS
Why it matters
The label moved BCMA-directed CAR T treatment earlier for patients already exposed to three major drug classes.
What research teams should watch
Verify the complete line history and document leukapheresis, bridging therapy and infusion readiness as separate milestones.
PRIMARY RECORDS